Press

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

Aug 3 • 3 min read

Reunion Neuroscience Inc. (TSX: REUN / NASDAQ: REUN), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact (“MPM“) are pleased to announce the completion of the previously announced plan of arrangement (the “Arrangement“) effective today, whereby MPM acquired Reunion in an all-cash transaction valued…

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Aug 3 • 4 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (“USPTO”), as part of…

Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent

Aug 3 • 3 min read

Optimi Health Corp. (CSE: OPTI / OTCQX: OPTHF / FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”), natural GMP-grade psilocybin, along with natural health product formulations, is pleased to announce the successful…

Psilocybin Potency, The Missing Link For Magic Mushroom Safety: Oakland’s Psychedelic Mushroom Church Announces Groundbreaking Information for Safe Use of Psilocybin Mushrooms

Jul 31 • 3 min read

The Church of Ambrosia, the largest psychedelic Church in the world with over 90,000 members, has announced important new safety information surrounding the use of psilocybin mushrooms by those seeking expanded consciousness in their spiritual quests. “The power of such experiences is transformative,” says Dave Hodges, who founded the Church of Ambrosia in 2019. “We…

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Jul 31 • 5 min read

PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is thrilled that it has filed a patent on the composition of matter of PharmAla-1. The patent filing follows a year of preclinical proof-of-concept research at the University of Arkansas…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441